Get the Stockscreener App
174.80
2.88%
4.89
Biogen Inc stock is traded at $174.80, with a volume of 14.98M.
It is up +2.88% in the last 24 hours and up +4.09% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$169.91
Open:
$171.32
24h Volume:
14.98M
Relative Volume:
7.29
Market Cap:
$25.64B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
16.72
EPS:
10.453
Net Cash Flow:
$1.85B
1W Performance:
+0.40%
1M Performance:
+4.09%
6M Performance:
+38.14%
1Y Performance:
+18.60%
1-Day Range:
$170.00
$176.42
1-Week Range:
$168.56
$176.42
52-Week Range:
$110.03
$185.17
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
174.80 | 24.93B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
1,071.44 | 945.93B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.37 | 501.88B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.82 | 393.81B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
136.06 | 259.56B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.09 | 249.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open - ts2.tech
Biogen (BIIB) Stock Trades Up, Here Is Why - FinancialContent
Is Biogen Inc. stock a bargain at current levelsJuly 2025 Price Swings & Safe Capital Investment Plans - Улправда
Biogen (NASDAQ:BIIB) Price Target Raised to $165.00 - MarketBeat
Why Biogen Inc. stock remains undervaluedInsider Buying & Daily Stock Momentum Reports - Улправда
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth - Pharma Voice
Biogen Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Biogen stock rated Outperform by RBC Capital with $210 price target - Investing.com Canada
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration - GuruFocus
What margin trends mean for Biogen Inc. stockMarket Sentiment Report & AI Enhanced Trading Alerts - Улправда
BMO Capital Adjusts Price Target on Biogen to $165 From $150, Maintains Market Perform Rating - marketscreener.com
Will Biogen Inc. stock outperform international peersJuly 2025 Intraday Action & Safe Entry Trade Reports - Улправда
Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound - Yahoo Finance
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress - Insider Monkey
Is Biogen a Mispriced Opportunity After Renewed Interest in Its Neurology Pipeline? - simplywall.st
BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Will Biogen Inc. stock benefit from sector rotation2025 Macro Impact & Verified Trade Idea Suggestions - Bollywood Helpline
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Disease Trial - marketscreener.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List - TradingView — Track All Markets
Pitcairn Co. Acquires Shares of 7,454 Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Valuation Check After Positive Neurology Data for Lecanemab and Zorevunersen - simplywall.st
Biogen Inc. (NASDAQ:BIIB) Doing What It Can To Lift Shares - 富途牛牛
Biogen’s New Study on BIIB145: A Potential Game-Changer for MS Treatment? - TipRanks
Alzheimer’s Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Biogen, Eisai, Eli Lilly and Company, AB Science, Alzheon, Inc., Cerecin, BioVie, Eisai Inc - Barchart.com
Biogen Doubles Down On Immunology As Lupus Programs Near Readouts - Citeline News & Insights
Biogen Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Biogen: Alzheimer's Disease Treatment Needs More Real-World Data (NASDAQ:BIIB) - Seeking Alpha
Hudson Bay Capital Management LP Buys 67,220 Shares of Biogen Inc. $BIIB - MarketBeat
Hudson Bay Capital Management LP Has $33.63 Million Position in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - Seeking Alpha
Biogen Inc. $BIIB Shares Purchased by Balyasny Asset Management L.P. - MarketBeat
Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index - marketscreener.com
Key facts: Biogen to release tau drug data; Morgan Stanley raises target; Jefferies hints at Nasdaq 100 removal - TradingView
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BII - GuruFocus
Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating - marketscreener.com
Boards of Appeal revoke Biogen’s dosage patent for Tecfidera - JUVE Patent
Alzheimer's drug hunt learns from cancer fight's multi-target playbook - marketscreener.com
State Street Corp Raises Position in Biogen Inc. $BIIB - MarketBeat
United States Controlled Release Drug Delivery Market to Reach - openPR.com
Axa S.A. Sells 45,397 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc (NASDAQ:BIIB) Nasdaq Composite ETF Neuro Innovation - Kalkine Media
Forecast 2035: Alzheimers Disease Diagnostic Market Size Set - openPR.com
Biogen (BIIB) Is Down 5.2% After HSBC Downgrade Amid Mixed Drug Pipeline Signals – Has The Bull Case Changed? - simplywall.st
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS - BioSpace
Biogen (NASDAQ:BIIB) Stock Rating Lowered by Hsbc Global Res - MarketBeat
Federated Hermes Inc. Acquires 17,069 Shares of Biogen Inc. $BIIB - MarketBeat
Why Analysts See Biogen’s Story Shifting Toward Undervalued Growth Potential - Yahoo Finance
Wells Fargo Maintains Biogen (BIIB) Equal-Weight Recommendation - Nasdaq
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):